Immune-Onc Therapeutics: Funding, Investors & Team (Oct 2026)
A recently founded biopharmaceutical business called Immune-Onc Therapeutics focuses on creating novel therapeutic antibodies for the treatment of cancer. The company advances novel immuno-oncology drugs and offers cancer patients new therapy alternatives by utilising the most recent scientific understandings and medication development capabilities.
Immune-Onc Therapeutics has raised $25.0M across 1 funding round on record, the most recent a Series B of $25.0M announced in Jan 2023.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Immune-Onc Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2023.
Immune-Onc Therapeutics Funding Rounds
Immune-Onc Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Immune-Onc Therapeutics Funding Compared to Other Biotechnology Startups
Immune-Onc Therapeutics' latest round of $25.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Immune-Onc Therapeutics in Biotechnology and Palo Alto
Companies Similar to Immune-Onc Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Immune-Onc Therapeutics Funding FAQs
What does Immune-Onc Therapeutics do?
A recently founded biopharmaceutical business called Immune-Onc Therapeutics focuses on creating novel therapeutic antibodies for the treatment of cancer. The company advances novel immuno-oncology drugs and offers cancer patients new therapy alternatives by utilising the most recent scientific understandings and medication development capabilities.
How much funding has Immune-Onc Therapeutics raised?
Immune-Onc Therapeutics has raised $25.0M across 1 round on record. The most recent is a Series B of $25.0M announced in Jan 2023.
When did Immune-Onc Therapeutics last raise funding?
Immune-Onc Therapeutics' most recent funding round on record is a Series B of $25.0M, announced in Jan 2023.
Who is the CEO of Immune-Onc Therapeutics?
Charlene Liao is listed as CEO at Immune-Onc Therapeutics.
Where is Immune-Onc Therapeutics headquartered?
Immune-Onc Therapeutics is based in Palo Alto, California, United States.
How many employees does Immune-Onc Therapeutics have?
Immune-Onc Therapeutics is in the 11-50 employee band.
How does Immune-Onc Therapeutics' funding compare to other Biotechnology startups?
Immune-Onc Therapeutics' latest round of $25.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Immune-Onc Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Immune-Onc Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.